Furthermore, in melanoma patients, serum IL8 levels were found to be linked with tumor size and stage, survival rates, and measurable treatment responses, including responses to BRAF inhibitors and immune-targeting monoclonal antibodies [71]. This evidence concerns the gene CXCL8 and melanoma.